IL154385A0 - Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses - Google Patents

Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Info

Publication number
IL154385A0
IL154385A0 IL15438501A IL15438501A IL154385A0 IL 154385 A0 IL154385 A0 IL 154385A0 IL 15438501 A IL15438501 A IL 15438501A IL 15438501 A IL15438501 A IL 15438501A IL 154385 A0 IL154385 A0 IL 154385A0
Authority
IL
Israel
Prior art keywords
necroses
tumours
plaques
imaging
representation
Prior art date
Application number
IL15438501A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL154385A0 publication Critical patent/IL154385A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL15438501A 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses IL154385A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
PCT/EP2001/008498 WO2002013874A2 (de) 2000-08-11 2001-07-23 Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen

Publications (1)

Publication Number Publication Date
IL154385A0 true IL154385A0 (en) 2003-09-17

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15438501A IL154385A0 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Country Status (26)

Country Link
EP (1) EP1307236A2 (xx)
JP (1) JP2004506025A (xx)
KR (1) KR20030022387A (xx)
CN (1) CN1469757A (xx)
AR (1) AR034139A1 (xx)
AU (2) AU7754901A (xx)
BG (1) BG107542A (xx)
BR (1) BR0113188A (xx)
CA (1) CA2419223A1 (xx)
CZ (1) CZ2003392A3 (xx)
DE (1) DE10066210B4 (xx)
EE (1) EE200300061A (xx)
HR (1) HRP20030173A2 (xx)
HU (1) HUP0300736A3 (xx)
IL (1) IL154385A0 (xx)
MX (1) MXPA03001287A (xx)
NO (1) NO20030604L (xx)
NZ (1) NZ523932A (xx)
PL (1) PL365596A1 (xx)
RU (1) RU2290206C2 (xx)
SK (1) SK1572003A3 (xx)
TW (1) TWI296931B (xx)
UA (1) UA82642C2 (xx)
WO (1) WO2002013874A2 (xx)
YU (1) YU10603A (xx)
ZA (1) ZA200301949B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2018052037A1 (ja) 2016-09-14 2018-03-22 ダイキン工業株式会社 分枝含フッ素化合物
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
KR20210095168A (ko) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
JPH10112939A (ja) * 1996-10-07 1998-04-28 Nec Corp 電源切替回路
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
CA2419223A1 (en) 2003-02-11
ZA200301949B (en) 2004-12-14
PL365596A1 (en) 2005-01-10
EE200300061A (et) 2004-12-15
AU2001277549B2 (en) 2007-02-08
MXPA03001287A (es) 2003-10-06
HUP0300736A2 (hu) 2003-09-29
KR20030022387A (ko) 2003-03-15
CN1469757A (zh) 2004-01-21
EP1307236A2 (de) 2003-05-07
BG107542A (bg) 2003-09-30
NZ523932A (en) 2007-07-27
HRP20030173A2 (en) 2005-04-30
DE10066210B4 (de) 2008-02-28
CZ2003392A3 (cs) 2003-09-17
RU2290206C2 (ru) 2006-12-27
SK1572003A3 (en) 2003-10-07
AU7754901A (en) 2002-02-25
WO2002013874A2 (de) 2002-02-21
BR0113188A (pt) 2003-06-24
AR034139A1 (es) 2004-02-04
NO20030604D0 (no) 2003-02-07
WO2002013874A8 (de) 2002-06-13
HUP0300736A3 (en) 2010-01-28
UA82642C2 (uk) 2008-05-12
YU10603A (sh) 2006-05-25
TWI296931B (en) 2008-05-21
JP2004506025A (ja) 2004-02-26
NO20030604L (no) 2003-04-11

Similar Documents

Publication Publication Date Title
IL259724B (en) 40-o-(2-hydroxyethyl)-rapamycin for use with an aromatase inhibitor in the treatment of breast tumors
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
IL154385A0 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
IL158985A0 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
EP1465997A4 (en) USE OF BIOMOLECULAR OBJECTIVES IN THE TREATMENT AND VISUALIZATION OF TUMORS
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
ITMI991764A0 (it) Nuovi complessi metallici utilizzabili nella catalisi per la co polime rizzazione della alfa-olefine
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
HUP0400997A3 (en) Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
EP1661548A4 (en) MEANS FOR ELIMINATION OF SINGLET OXYGEN AND THIS USE METHOD
EP1390689A4 (en) REDUCTION OF COHERENT ARTIFACTS IN AN INTERFEROMETER
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
IL159879A0 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
AU2003281146A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes
AU2003233431A8 (en) Protamine-adenoviral vector complexes and methods of use
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
IL152388A0 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
EP1383543A4 (en) USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS
GB0022081D0 (en) Pyrazolone lanthanide complexes
GB0106316D0 (en) Apparatus for use in the treatment of hair
EP1677958A4 (en) INSULATION USED IN THE MOLDING OF METALS CONTAINING IRON COMPOUNDS
IL146655A0 (en) The use of leptin in fertility
AU2002354738A1 (en) Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours